Cadila gets USFDA nod for Pyridostigmine Bromide tablets

Published - June 24, 2015 12:27 pm IST - New Delhi

Drug firm Zydus Cadila has received approval from the US health regulator to market its Pyridostigmine Bromide Tablets, used for treating various neurological disorders.

With this approval, the group has received 100 approvals and has so far filed 260 ANDAs (abbreviated new drug applications).

The company has received final approval from the US Food and Drug Administration (USFDA) to market Pyridostigmine Bromide Tablets USP, 60 mg, Zydus Cadila said in a filing to BSE.

According to IMS Health data, the estimated sales in 2015 for these tablets was USD 27.9 million.

Shares of Zydus Cadila were trading at Rs 1,774.50 on BSE, up 2.48 per cent in the early morning trade.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.